2024-05-31 00:38:00
Pfizer, CROWN Study: Lorviqua 5-year follow-up data demonstrate increased progression-free survival in NSCLC
These data will be presented today at the Annual Congress ofAmerican Society of Clinical Oncology (ASCO) (Abstract LBA8503) and published simultaneously on Journal of Clinical Oncology. “The data from the CROWN study are unprecedented, as the majority of patients treated with lorlatinib live, without disease progression, beyond five years”, he declared Roger DanseyMD, Director of Development, Oncology, Pfizer. “These results demonstrate Pfizer’s long-standing commitment to oncology research, development and innovation and establish lorlatinib as the standard of care for the front-line treatment of adult patients with non-small cell lung cancer (Non-Small Cell Lung Cancer, NSCLC) in advanced stage ALK-positive”.
Lung cancer represents the leading cause of cancer death in the world and it is estimated that 234,580 new cases will be diagnosed in 2024 in the United States. The NSCLC represents approximately 80-85% of lung tumors. Tumor forms ALK-positive they are present in approximately 3-5% of NSCLC cases. About 25 to 40 percent of people with ALK-positive advanced NSCLC may develop brain metastases within two years of initial diagnosis. Lorlatinib it was specifically developed by Pfizer to inhibit tumor mutations that lead to resistance to other ALK inhibitors and to penetrate the blood brain barrier.
“Advanced ALK-positive NSCLC is typically aggressive and often affects young people in the prime of their lives”, he declared Benjamin SolomonMBBS, Ph.D., Department of Medical Oncology, Peter MacCallum Cancer Centre, and Principal Investigator of the CROWN study. “This updated analysis shows that lorlatinib helped patients live longer without disease progression, with most experiencing lasting benefits for more than five years, and nearly all without disease progression in the brain. These improvements in outcomes for patients with ALK-positive NSCLC represent a truly remarkable advance in the treatment of lung cancer”.
Lorlatinibfurthermore, it showed a reduction in 94% of the risk of developing intracranial (IC) progression (HR, 0.06; 95% CI, 0.03-0.12). The median time to CI progression was not reached (95% CI, NR-NR) with lorlatinib and was 16.4 months (12.7-21.9) with crizotinib. In people without brain metastases at baseline who received lorlatinib, only 4 is 114 developed brain metastases within the first 16 months of treatment, compared to 39 of 109 patients who received crizotinib. At the time of the analysis, 50% of patients in the CROWN study were still receiving lorlatinib, compared to 5% of patients who had received crizotinib.
“Although ALK-positive advanced NSCLC only accounts for about five percent of all NSCLC cases, this translates to 72,000 people diagnosed each year worldwide”, he declared Kenneth CulverMD, Director of Research and Clinical Affairs of the non-profit organization ALK Positive. “These new results from the CROWN study represent a significant advance in the first-line treatment of ALK-positive lung cancer, leading to important improvements for the patient community”.
#Pfizer #CROWN #Study #superiority #lorlatinib #crizotinib #confirmed